GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, today reported financial results for the second quarter of 2026 and provided a business update, emphasizing continued execution toward the planned initiation of a pivotal immunobridging study for its lead vaccine candidate, GEO-MVA. The company is pursuing an expedited regulatory pathway supported by Scientific Advice from the European Medicines Agency (EMA).
During the quarter, GeoVax advanced clinical operations planning, start-up activities, and manufacturing preparedness. The company has already manufactured and released cGMP clinical trial material for the study. Additionally, GeoVax is advancing its AGE1 continuous cell-line manufacturing platform to support future commercial-scale MVA vaccine production. Engagement with government, public health, and biodefense stakeholders continues to address long-term orthopoxvirus preparedness and vaccine supply requirements.
“During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study,” said David A. Dodd, Chairman and CEO of GeoVax. “Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense.”
GeoVax also provided an update on its Gedeptin immuno-oncology program. Gedeptin is an investigational gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin’s localized tumor-targeting mechanism may complement PD-1-based therapies like Merck’s Keytruda. GeoVax holds an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
For the second quarter of 2026, GeoVax reported a net loss of $4.43 million, or $0.97 per share, compared to a net loss of $5.37 million, or $8.74 per share, in the same period of 2025. The improvement in net loss was driven by lower operating expenses. Research and development expenses decreased to $3.11 million from $4.73 million, primarily due to the discontinuation of activities related to the BARDA contract for the GEO-CM04S1 COVID-19 vaccine program. General and administrative expenses fell to $1.33 million from $1.54 million, reflecting lower investor relations consulting costs and reduced stock-based compensation.
GeoVax ended the quarter with approximately $3.1 million in cash, consistent with the end of 2025. The company has strategically reprioritized its portfolio to focus on GEO-MVA and Gedeptin, discontinuing active development of its COVID-19 vaccine candidate due to market contraction. The company believes these programs offer the strongest combination of clinical differentiation, regulatory clarity, and commercial opportunity.
Additional information is included in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. The original press release is available on NewMediaWire.
